- Resminostat/sorafenib combination therapy halts further disease progression in two thirds of patients (PFSR 66.6%) and achieves median progression-free survival (PFS) of 4.6 months - First ...
Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an ...
Evotec AG / / Ad hoc:Evotec acquires compound management business from Galapagos . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results